Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of nomlabofusp in Friedreich’s ataxia (FA), revealing meaningful improvements in biomarkers and functional outcomes. These findings highlight nomlabofusp’s potential to become the first disease-modifying therapy for this rare neurodegenerative condition.
Science Significance
The study showed that daily administration of nomlabofusp increased skin frataxin (FXN) levels, with 100% of participants achieving more than 50% of the FXN levels observed in healthy individuals after six months. Improvements were also observed across four critical clinical endpoints—mFARS, FARS-ADL, 9-HPT, and MFIS—suggesting that restoring FXN may provide tangible functional benefits. This evidence strengthens the scientific rationale that nomlabofusp could directly address the root cause of FA.
Regulatory Significance
Larimar Therapeutics has maintained regular interactions with the U.S. Food and Drug Administration (FDA) under the START (Support for Clinical Trials Advancing Rare Disease Therapeutics) program. The company plans a Biologics License Application (BLA) submission seeking accelerated approval in Q2 2026. Recent FDA alignment on safety and dosing adjustments further supports the regulatory pathway for nomlabofusp.
Business Significance
Advertisement
The continued advancement of nomlabofusp enhances Larimar’s leadership in rare disease innovation. With a global Phase 3 study preparing to launch across the U.S., Europe, Canada, U.K., and Australia, the therapy holds strong commercial potential in orphan drug markets. If successful, nomlabofusp could become a first-in-class therapy for Friedreich’s ataxia, creating both medical impact and strategic value for the company.
Patients’ Significance
For patients with Friedreich’s ataxia, a progressive and life-shortening disorder, nomlabofusp represents a potential lifeline. Achieving FXN levels comparable to asymptomatic carriers offers hope for slowing or halting disease progression. Families and advocacy groups have expressed keen interest in accessing such therapies, as current treatment options remain limited to symptom management rather than modifying disease trajectory.
Policy Significance
Nomlabofusp’s progress demonstrates the importance of regulatory initiatives that accelerate rare disease therapies. Programs like FDA’s START pathway are critical to ensuring timely development and approval of treatments for underserved populations. Continued policy support for rare disease research and innovation will be essential in enabling therapies like nomlabofusp to reach patients more quickly.
With long-term data showing increased frataxin levels, improved functional outcomes, and manageable safety, Larimar Therapeutics’ nomlabofusp is emerging as a leading candidate to transform the treatment of Friedreich’s ataxia. As regulatory submissions near and Phase 3 studies expand globally, this program represents a pivotal moment for patients and for the future of rare disease therapies.
Source: Larimar Therapeutics press release
